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Abstract
As perinatally HIV-1-infected children grow into adolescents and young adults, they are increasingly burdened with the
long-term consequences of chronic HIV-1 infection, with long-term morbidity due to inadequate immunity. In progressive
HIV-1 infection in horizontally infected adults, inflammation, T cell activation, and perturbed T cell differentiation lead to an
‘‘immune exhaustion’’, with decline in T cell effector functions. T effector cells develop an increased expression of CD57 and
loss of CD28, with an increase in co-inhibitory receptors such as PD-1 and Tim-3. Very little is known about HIV-1 induced T
cell dysfunction in vertical infection. In two perinatally antiretroviral drug treated HIV-1-infected groups with median ages of
11.2 yr and 18.5 yr, matched for viral load, we found no difference in the proportion of senescent CD282CD57+CD8+ T cells
between the groups. However, the frequency of Tim-3+CD8+ and Tim-3+CD4+ exhausted T cells, but not PD-1+ T cells, was
significantly increased in the adolescents with longer duration of infection compared to the children with shorter duration
of HIV-1 infection. PD-1+CD8+ T cells were directly associated with T cell immune activation in children. The frequency of
Tim-3+CD8+ T cells positively correlated with HIV-1 plasma viral load in the adolescents but not in the children. These data
suggest that Tim-3 upregulation was driven by both HIV-1 viral replication and increased age, whereas PD-1 expression is
associated with immune activation. These findings also suggest that the Tim-3 immune exhaustion phenotype rather than
PD-1 or senescent cells plays an important role in age-related T cell dysfunction in perinatal HIV-1 infection. Targeting Tim-3
may serve as a novel therapeutic approach to improve immune control of virus replication and mitigate age related T cell
exhaustion.
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Introduction
Since the advent of antiretroviral drugs, perinatally HIV-1-
infected children have grown up into the adolescent age with lower
rates of AIDS related mortality and morbidity [1,2,3,4,5]. Despite
combination antiretroviral therapy (cART), perinatally HIV-1
infected subjects have striking differences in HIV-1 disease
progression compared to adults and adolescents and have higher
viral load (VL) and lower virological responses rates than adults
[6,7,8,9]. This is primarily as a consequence of poor adherence to
drugs over a lifetime, underdosing, treatment fatigue, altered
pharmacokinetics, novel toxicities, caregiver-related problems and
high rates of psychiatric illness including the complications of long-
standing infection and the deleterious effects of cART
[6,10,11,12]. In horizontally infected adults with chronic treated
HIV-1 infection, it is evident that mortality due to non-AIDS
events is more common than mortality due to AIDS-related events
[13] and this could potentially occur in perinatally infected
children earlier. As perinatally HIV-1-infected children age with
HIV-1, deleterious consequences to protective T cell immunity
may persist or develop despite cART [6,14]. The exact nature of
these immunological events and the association with disease
progression in vertically infected patients remain unclear.
On encountering antigen, CD8+ T cells differentiate from the
least differentiated (naive or early memory) stage to the most
mature (memory/effector) stage. In this process, cell surface
receptors are progressively downregulated (CD45RA, CCR7,
CD28, CD27, CD127) or upregulated (CD57 and CD45RA) as
CD8+ T cells differentiate [15,16,17,18]. In adults with HIV-1
infection, T cells fail to fully mature into effector T cells
[19,20,21]. We have previously shown that the differentiation
status of HIV-1 specific T cells in adults were not readily altered
by cART despite declines in T cell activation suggesting that
cART does not reverse T cell effector defects [14]. We further
showed that in perinatally infected children, T cell effector
maturation induced by HIV-1 infection was markedly weaker
compared to adults, even in those on cART [22]. As HIV-1
specific T cells develop increased CD57 expression, they have
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replicative senescence [23], and remain senescent despite
suppressive cART.
During many chronic viral infections a distinct terminal state of
T cell differentiation, or T cell exhaustion arises [24,25]. Such
functionally impaired T cells are characterized by abnormally low
cytokine production, poor proliferative capacity with the upregu-
lation of several inhibitory receptors including Programmed
Death-1 (PD-1) and T-cell immunoglobulin and mucin domain-
containing molecule-3 (Tim-3) among others [26,27,28,29]. These
receptors not only mark but also induce inhibitory signals to
dampen T cell immune responses. In HIV-1 infection, PD-1, a
CD28 family member, is increased on CD8+ T cells in progressive
HIV-1 disease [30,31]. Tim-3, an immunoglobulin (Ig) superfam-
ily member, initially identified as a negative regulator of Th1
response through the Tim-3/Galectin-9 pathway in several
inflammatory disease states [32,33], is also elevated in HIV-1
disease [30] and associated with disease progression. cART can
reduce PD-1 levels in T cells in HIV-1 infected adults, and in some
subjects Tim-3 expression is also reduced [30,34]. Several
combinations of markers are therefore used to discriminate
differentiated and senescent T cells. However, whether there are
common mechanisms regulating them remain unclear [35].
In the setting of treated HIV-1 disease in adults, T cell function
remains perturbed with CD8+ T cell activation, defined by CD38+
or CD38+HLA-DR+ coexpression, at higher levels than in
uninfected subjects [14,36,37]. Immune activation occurs in
perinatally infected children and the degree of immune activation
present as early as 1–2 months of age can be used to predict which
children will become long-term non-progressors [38,39]. In
children, the relationship between HIV-1 viral load and immune
activation appears to be less clear-cut than in adults, in whom a
higher level of viremia is predictably associated with higher levels
of activation [38,39,40]
As adults with HIV-1 infection age, it appears that alterations in
immune profile or immunosenescence begin to resemble those of
much older uninfected subjects, and is now referred to as
‘‘premature aging’’ [41,42,43]. Phenotypic and functional T cell
alterations observed during advancing human age lead to poor
responses to and efficacy of vaccines, and increased susceptibility
to new infections and tumors in the elderly [44,45]. With an
acceleration of aging and T cell decline induced by HIV-1
infection, a similar impact on T cell immunity could occur in
perinatal HIV-1 infected children as they age into adolescenthood.
In this study we sought to assess the effects of HIV-1 infection
on T cell differentiation, senescence and exhaustion in two age
groups of perinatally HIV-1-infected subjects with shorter and
longer durations of infection that present with persistently high
HIV viremia despite access to cART, and determine the
associations with markers for disease progression (viral load,
immune activation) to improve our understanding of how these
parameters may modulate the ability of protective T cell immunity
to control HIV infection in children.
Materials and Methods
Ethics Statement
The research involving human participants reported in this
study was approved by University of California, San Francisco
(UCSF) and Albert Einstein College of Medicine (AECOM)
institutional review boards (IRBs), with the approval numbers 10-
04893 (UCSF) and 1999-255-000 (AECOM). The legal guardians
(biological parent, adoptive parent etc.) provided written informed
consent for these patients. For children above 12 years of age,
signed consent on the regular informed consent document along
with their legal guardians was obtained; for children between the
ages of 7 through 12, child assent was also required and obtained;
for children less than 7 years old, only the legal guardian provided
written consent. The research was conducted according to the
Declaration of Helsinki.
Study Population
The study population included 16 perinatally HIV-infected
subjects from the Jacobi Medical Center, Bronx, New York.
Whole blood samples were collected in EDTA tubes from the
subjects during their scheduled monthly visit after obtaining
informed consents. Peripheral blood mononuclear cells (PBMC)
were purified using Ficoll-PaqueTM PLUS density gradient
centrifugation (Amersham Pharmacia Biotech, Uppsala, Sweden).
Cells were frozen in media containing 90% fetal bovine serum
(HyClone, Logan, UT) and 10% dimethyl sulfoxide (Sigma
Aldrich, St. Louis, MO) and stored in liquid nitrogen. All subjects
were under the care of pediatricians at the Jacobi Medical Center,
Bronx, New York.
Measurement of Viral Load
Plasma HIV-1 viral load (VL) was measured with Amplicor
HIV-1 Monitor with a lower limit of detection of 50 copies of
RNA/ml (Roche Diagnostic Systems, Branchburg, NJ).
Flow Cytometry Assessment
Cryopreserved PBMC were thawed in 37uC water bath, washed
in RPMI-1640 medium (HyClone, Logan, UT) supplemented
with 10% fetal bovine serum. The PBMC were used in two
different panels for surface staining. Briefly, 16106 PBMC were
washed in FACS buffer (PBS+0.02% EDTA and 1% BSA) and
transferred to a 96-well V-bottom plate, surface stained for
different surface markers for 30 minutes on ice followed by
washing in FACS buffer twice and then fixing in 1% paraformal-
dehyde (Polysciences, Niles, IL) on ice. Finally, cells were analyzed
on a LSRII flow cytometer (Becton Dickinson, San Jose, CA). The
data was analyzed with FlowJo software, version 9.0 (Tree Star,
Ashland, OR). Panel 1 included PE-anti-CD38 (BD Biosciences,
San Jose, CA), FITC-anti-HLA-DR (BD Biosciences), Alexa 700-
anti-CD4 (BD Biosciences), Qdot 605-anti-CD8 (Invitrogen,
Carlsbad, CA), ECD-anti-CD3 (Beckman Coulter, Brea, CA).
Panel 2 had PE-anti-Tim-3 (R&D System, Minneapolis, MN)
APC-anti-PD-1 (Biolegend, San Diego, CA), Alexa 700-anti-CD4
(BD Biosciences), ECD-anti-CD3 (Beckman Coulter), APC Cy7-
anti-CD8 (BD Biosciences), PE-Cy7-anti-CD28 (eBiosciences, San
Diego, CA), and FITC-anti-CD57 (BD Biosciences). An amine
aqua dye (Invitrogen) was also included in both panels to
discriminate between live and dead cells.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
statistical software (GraphPad Software, San Diego, CA). The
nonparametric Mann-Whitney U was used for comparison tests,
and the Spearman Rank test was used for correlation analyses.
Results
Human Subjects
Sixteen HIV-1-infected pediatric subjects of Hispanic and Black
ethnicity were divided into two groups based on age. The median
age of the two groups consisting children (n= 6) and adolescents
(n = 10) was 11.2 and 18.5 years, respectively (Table 1). The two
groups were matched for viral load and CD4 count (Table 1). All
except three subjects in adolescents were on cART with variable
Immune Exhaustion in Perinatal HIV-1 Infection
PLOS ONE | www.plosone.org 2 September 2012 | Volume 7 | Issue 9 | e45733
adherence to antiretroviral treatment. The characteristics of both
groups are displayed in table 2.
There are similar proportions of CD282/CD57+ T cells in
children and adolescents
T cell immunosenescence is characterized by the complete and
permanent loss of CD28+ T cells [16,17] and elevated expression
of CD57 on CD8+ T cells [18]. To analyze the effect of the
duration of HIV-1 infection and aging process on the T cell
immune response, we assessed T cell differentiation and senes-
cence (CD28+, CD57+, and CD57+CD282) of both CD4+ and
CD8+ T cells in two perinatally HIV-1 infected age groups on
cART. We observed that CD8+ and CD4+ T cells did not show
any difference in their senescence level between children and
adolescents with shorter and longer duration of HIV-1 infection
respectively, as observed by CD57+ (CD8: median 34.83%; IQR
22.84, 47.83 versus median 29.33%; IQR 21.29, 37.10; p = 0.367,
figure 1A and B; CD4: median 1.18%; IQR 0.81, 5.87 versus
median 1.84%; IQR 1.20, 4.88; p= 0.493, figure 2A and B),
CD282 (CD8: median 55.27%; IQR 36.42, 66.60 versus median
65.22%; IQR 54.66, 72.59; p = 0.263 figure 1A and B; CD4:
median 2.21%; IQR 1.31, 6.67 versus median 0.38%; IQR 0.18,
5.97; p = 0.117, figure 2A and B) and CD57+CD282 (CD8:
median 31.55%; IQR 18.64, 39.52 versus median 24.61%; IQR
19.81, 31.88; p = 0.427, figure 1A and B; CD4: median 0.36%;
IQR 0.10, 3.14 versus median 0.23%; IQR 0.07, 2.48; p = 0.792,
figure 2A and B) levels.
Expansion of Tim-3+CD4+ and CD8+ T cells in perinatally
HIV-1 infected adolescents
In contrast to HIV-1 infection in adults, we did not observe any
age related alterations in CD57 or CD28 T cell expression [18,46].
We next assessed the expression of the inhibitory receptors, Tim-3
and PD-1. Compared to younger group, the frequency of Tim-3 in
older group was increased in both CD8+ (median 18.35%; IQR
13.14, 20.95 versus median 23.93%; IQR 18.19, 32.94;
*p = 0.045, figure 1C and D) and CD4+ (median 11.94%; IQR
10.04, 13.51 versus median 21.34%; IQR 16.47, 23.51;
**p = 0.003, figure 2C and D) T cells. There was no significant
difference in PD-1+CD8+ (median 40.05%; IQR 27.68, 55.80
Table 1. Numbers, CD4 count, viral load, CD8+ T cell activation, and age of subjects in each group.
Measurement Children Adolescents P-value
N 6 10
Median CD4+T cell count (cells/mm3 [IQR]) 547 (299–1,223) 380.5 (338.5–426.5) 0.41
Median HIV-1 viral load (log10 c/ml [IQR]) 3.8 (2.8–4.7) 4.5 (4.0–4.8) 0.18
Median CD8+ T cell activation (% CD38, HLA-DR [IQR]) 33.05 (19.95–37.98) 16.15 (16.17–29.63) 0.103
Median age (yr [IQR]) 11.2 (11.0–11.8) 18.5 (17.4–19.9) 0.0002*
doi:10.1371/journal.pone.0045733.t001
Table 2. Subject characteristics.
Group Patient ID Age (in yrs) R/E* Sex ART1 Notes
Children S1 11.0 W/H M ABC, 3TC, ATV/r -
S2 11.0 B/NH F ddI, 3TC, LPV/r Variable adherence.
S3 11.1 W/H M d4T, EFV, LPV/r Excellent adherence.
S4 11.4 B/H F ABC, 3TC, ATV/r -
S5 11.8 W/H F ZDV, 3TC Long term PTI patient.
S6 12.0 B/NH F ZDV, 3TC -
Adolescents P1 19.3 W/H M On etravirine study Complete non-adherence to ART.
P2 19.6 W/H F ZDV, 3TC, LPV/r 2nd trimester pregnancy, improved
adherence.
P3 21.2 B/NH M EFV-based HAART Variable adherence.
P4 22.8 W/H M TDF, FTC, ddI, ATV -
P5 18.5 W/H M ZDV, 3TC -
P6 18.6 W/H F No ARVs Off ARVs for .2 yrs.
P7 18.0 B/NH F No ARVs AIDS, HIV nephropathy, on
hemodialysis, non-adherence.
P8 17.7 W/H F ZDV, 3TC, ABC, TDF, ATV/r Complete non-adherence to ART.
P9 16.5 W/H M No ARVs Off ARVs for .2 yrs.
P10 16.3 W/H F ZDV, 3TC, ABC, RTV Poor adherence.
R/E = Race/Ethnicity, W/H =White/Hispanic, B/NH= Black/Non-Hispanic,
1ART=Antiretroviral treatment, ZDV= Zidovudine, 3TC = Lamivudine (29, 39-dideoxy-39-thiacytidine), ABC =Abcavir, TDF = Tenofovir disoproxil fumarate, ATV/
r = Atazanavir/ritonavir, LPV/r = Lopinavir/ritonavir, ddI =Didanosine, EFV = Efavirenz.
doi:10.1371/journal.pone.0045733.t002
Immune Exhaustion in Perinatal HIV-1 Infection
PLOS ONE | www.plosone.org 3 September 2012 | Volume 7 | Issue 9 | e45733
Figure 1. Expansion of Tim-3+CD8+ T cells in perinatally HIV-1-infected adolescents. (A) Flow dot plots show CD8+ T cell surface
expression of CD28 and CD57 in perinatally HIV-1-infected children with shorter duration of HIV-1 infection (median: 11.2 y) and adolescents with
longer duration of HIV infection (median:18.5 y). (B) Frequencies of CD282, CD57+, and CD57+CD282 CD8+ T cells in perinatally HIV-1-infected
children and adolescents. (C) Flow dot plots show CD8+ T cell surface expression of PD-1 and Tim-3 in perinatally HIV-1-infected children with shorter
duration of HIV infection (median: 11.2 y) and adolescents with longer duration of HIV-1 infection (median: 18.5 y). (D) Frequencies of Tim-3+, PD-1+,
and PD-1+ Tim-3+CD8+ T cells in perinatally HIV-1-infected children and adolescents. A significant increase in Tim-3+CD8+ T cell (*p = 0.045) population
was observed with age. P values were obtained using two-tailed Mann-Whitney U test. Flow dot plots are representative of all subjects in respective
groups.
doi:10.1371/journal.pone.0045733.g001
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Figure 2. Expansion of Tim-3+ CD4+ T cells in perinatally HIV-1-infected adolescents. (A) Flow dot plots show CD4+ T cell surface
expression of CD28 and CD57 in perinatally HIV-1-infected children with shorter duration of HIV-1 infection (median: 11.2 y) and adolescents with
longer duration of HIV infection (median:18.5 y). (B) Frequencies of CD282, CD57+, and CD57+CD282 CD4+ T cells in perinatally HIV-1-infected
children and adolescents. (C) Flow dot plots show CD4+ T cell surface expression of PD-1 and Tim-3 in perinatally HIV-1-infected children with shorter
duration of HIV infection (median: 11.2 y) and adolescents with longer duration of HIV-1 infection (median: 18.5 y). (D) Frequencies of Tim-3+, PD-1+,
and PD-1+ Tim-3+CD4+ T cells in perinatally HIV-1-infected children and adolescents. A significant increase in Tim-3+CD4+ T cell (**p = 0.003)
Immune Exhaustion in Perinatal HIV-1 Infection
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versus median 36.75%; IQR 28.58, 51.71; p = 0.874, figure 1C
and D) or PD-1+CD4+ (median 9.43%; IQR 4.82, 18.46 versus
median 17.14%; IQR 9.48, 23.58; p = 0.263, figure 2C and D)
and Tim-3+PD-1+CD8+ (median 5.55%; IQR 4.52, 6.67 versus
median 6.23%; IQR 3.59, 12.07; p= 0.56, figure 1C and D) or
Tim-3+PD-1+CD4+ T cell (median 2.26%; IQR 1.69, 3.76 versus
median 4.08%; IQR 2.39, 7.67; p= 0.147, figure 2C and D) T cell
population between groups. This suggests that Tim-3+ T cell
expansion and not PD-1 is potentially driven by infection duration
and possibly by age, and serves as a better marker for age related
T cell dysfunction in the context of perinatal HIV-1 infection.
Tim-3+CD8+ T cell expression and not PD-1+ is associated
with HIV-1 viral load in adolescents with longer infection
We and others previously observed that Tim-3 and PD-1 on
CD8+ T cells are associated with HIV-1 viral load in adults [47].
We next determined whether the levels of Tim-3 or PD-1 on T
cells were associated with HIV-1 plasma viral load. Interestingly,
Tim-3+CD8+ T cells showed a significant direct association with
HIV-1 plasma viral load in the adolescents (Figure 3B, *p = 0.017,
r=0.74), while no such association existed in the children
(Figure 3A). PD-1+CD8+ T cells did not associate with HIV-1
plasma viral load in either of age groups (Figure 3C and D). Tim-
3+CD4+ T cells did not show any association with HIV-1 plasma
viral load in both children (Figure S1A) and adolescents (Figure
S1B). However PD1+CD4+ T cells were directly associated with
HIV-1 plasma viral load in children (Figure S1C, *p= 0.033,
r=0.88) but not in adolescents (Figure S1D).
Infection duration and age related decline in CD8+ T cell
activation in the adolescents with longer HIV infection
T cell activation, as defined by the expression of HLA-DR and
CD38, is the marker of HIV-1 disease progression [37,48,49]. In
perinatally HIV-1 infected children, CD38 expression in CD8+ T
cells predicts virological failure despite antiretroviral therapy [50].
We determined next whether the levels of CD38 and HLA-DR or
CD38 alone were associated with T cell activation. Given that
perinatally HIV-1 children have a high HIV-1 load and poor
adherence to cART, we hypothesized that perinatally HIV-1-
infected children would show higher immune activation with
advancing age. However, when we looked at treatment-experi-
enced subjects from the two groups, we observed a decrease in
immune activation in the adolescent group only, despite no
significant change in viral load and CD4+ count in both groups.
population was observed with age. P values were obtained using two-tailed Mann-Whitney U test. Flow dot plots are representative of all subjects in
respective groups.
doi:10.1371/journal.pone.0045733.g002
Figure 3. A positive correlation between Tim3+CD8+ T cells and HIV-1 plasma viral load (VL) in adolescents. Scatter plots showing
correlation between HIV plasma viral load (VL) and Tim-3+CD8+ T cells (A and B), and PD-1+CD8+ T cells (C and D) in children (left) and adolescents
(right) subjects. Tim-3+CD8+ T cells show a significant direct correlation with HIV-1 plasma viral load (VL) in adolescents (Spearman r = 0.74,
*p = 0.017).
doi:10.1371/journal.pone.0045733.g003
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There was a marginal decrease in HLA-DR+CD38+CD8+ T cells
in adolescents, while CD38+CD8+ T cells were significantly
(*p = 0.016) decreased in adolescents (Figure 4A and B). The
changes in immune activation were independent of HIV-1 plasma
viral load (data not shown).
PD-1+CD8+ T cells are associated with T cell activation
but not viral load
We next assessed the relationship between T cell exhaustion and
immune activation. Intriguingly, PD-1+CD8+ T cells had a direct
strong significant association with HLA-DR+CD38+CD8+ T cells
in children (r = 0.947, **p = 0.004) as well as in the adolescents
(r = 0.70, *p= 0.026). This suggests that there is a possibility that
PD-1 expression may be driven by immune activation (Figure 5A
and B). Tim-3 did not show any association with immune
activation in either group (Figure 5C and D).
Discussion
Despite access to cART, children aging with HIV-1 infection
are unable to control HIV-1 infection adequately [51]. Therefore,
it is imperative to determine better correlates of protective
immunity. This study shows that markers of T cell senescence
do not appear to change with the duration of infection. However,
there was an expansion of immune exhausted Tim-3+CD8+ T
cells, but not PD-1+ T cells, in adolescents compared to younger
children in the setting of high viremia. More importantly, these
high levels of Tim-3+CD8+ T cells had a significant direct
association with HIV-1 plasma viral load.
The expression of the inhibitory molecules Tim-3 and PD-1 on
CD8 T cells has been associated with T cell exhaustion during
chronic HIV-1 infection in adults. Their expression results in
inhibition of T cell expansion and cytokine production [29,30,47],
and associate with disease progression. A recent study has shown
that PD-1 increased on T cells derived from older mice compared
to younger mice [52], suggesting these exhaustion markers may
contribute to age-related declines in immunity. Our data suggest
that Tim-3 plays an important role in age-related T cell
dysfunction in perinatal HIV-1 infection. By contrast, neither
PD-1+ nor PD1+Tim-3+ T cells showed any difference in the two
age groups in our study. While we did not observe differential PD-
1 expression, this may be due to the small differences in age
between the two groups in our study, or may reflect differences in
the dynamics of PD-1 and Tim-3 expression.
T cell activation is undoubtedly the best marker of HIV-1
disease in adults. We and others have shown that HIV-1 viral load
directly associates with T cell activation (HLA-DR+CD38+ or
CD38+) in adults [53,54], but this does not appear to occur in
pediatric vertical infection which has also been confirmed by
others [55]. Tim-3+ CD8+ T cells are not associated with T cell
activation [30]. Our results are consistent with a recent report that
shows a positive association between CD8+ T cell activation and
Figure 4. Infection duration and age related decrease in CD8+ T cell activation in adolescents. (A) Flow dot plots show CD8 surface
expression of CD38 and HLA-DR in perinatally HIV-1 infected children (median: 11.2 y) and adolescents (median: 18.5 y). Dot plots are representative
of all subjects in respective groups. (B) Frequencies of HLA-DR+CD38+CD8+ T cells and CD38+CD8+ T cells in perinatally HIV-1-infected children and
adolescents. A significant decrease in CD38+CD8+ T cell (*p = 0.016) and a marginal decrease in HLA-DR+CD38+CD8+ T cell (p = 0.103) populations
were observed with the duration of HIV infection. P values were obtained using two-tailed Mann-Whitney U test.
doi:10.1371/journal.pone.0045733.g004
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the frequency of PD-1+CD8+ T cells in HIV-1 infected untreated
younger children [56]. PD-1 may thus serve as a marker of T cell
activation and our results build on this observation. Our previous
study revealed that CD38 is associated with HIV-1 viral load [53].
We found that CD38 alone was lower in the adolescents with
longer duration of HIV-1 infection despite both age groups having
similar matched HIV-1 viral load.
T cell immunosenescence is characterized by the complete and
permanent loss of CD28+ T cells and elevated expression of CD57
on CD8+ T cells [41,43]. Compared to age-matched controls,
HIV-1-infected adults have noticeable increase in CD282 and
CD57+ CD8+ T cell population [57,58,59]. In addition,
CD282CD8+ T cells have been shown to be significantly
associated with the CD4+ T cell loss, and lymphocyte apoptosis
in perinatally HIV-1-infected children [60]. In our present study,
we expected an accumulation of CD57+CD282 T cells in the
adolescents with longer duration of infection. However, unlike
adult HIV-1 infection, we did not observe any changes in these cell
subsets in pediatric HIV-1 infection. These observations suggest
that the previous published senescent markers (CD28, CD57) in
adults may not reflect age related changes in perinatally HIV-1-
infected children. Instead, Tim-3 may be a better marker of T cell
immunosenescence in children and adolescents.
Due to the complexities in the management of perinatal HIV
infection, and its accompanying specific treatment related issues,
novel strategies are needed. Earlier initiation of cART follow by
partial treatment interruption (PTI) is being reconsidered and
envisioned to permit functional maturity of protective T-cell based
immunity before introduction of a PTI regimen [61]. A recent
study showed that adherence rates to antiretroviral therapy
remained the same between PTI and continuous therapy (CT)
[62]. Our previous work has shown that PTI was ineffective in
controlling HIV-1 replication [63]. We propose that defining
effective phenotypic profile of protective T cell immunity and
reinvigorating T cell immunity by targeting age dependent
pathways like Tim-3 may help induce effective anti-HIV-1
immune responses in children on either CT or PTI and be
considered as an adjunctive therapy.
Figure 5. PD-1+CD8+ T cells have a strong significant correlation with immune activation in both age groups. Scatter plots showing a
correlation between immune activation and PD-1+ or Tim3+CD8+ T cells. (A) and (B) show a significant strong correlation between HLA-
DR+CD38+CD8+ T cell and PD-1+CD8+ T cells in children with shorter duration of HIV-1 infection (Spearman r = 0.947, **p = 0.004) and adolescents
with longer duration of HIV-1 infection (Spearman r = 0.70, *p = 0.026) respectively. (C) and (D) show a correlation between HLA-DR+CD38+ CD8+ T
cells and Tim-3+CD8+ T cells in both age groups.
doi:10.1371/journal.pone.0045733.g005
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It is still debated whether T cell senescence and exhaustion are
related or unrelated processes in compromised immunity. Detailed
assessment of the signaling pathways that regulate T cell
senescence and exhaustion suggest that they appear to be distinct
processes [35]. Our study design did not permit the assessment of
multiple age groups to determine the shifts in the profiles of the T
cell differentiation and exhaustion markers over time in both HIV-
1-infected and uninfected children. Therefore, further studies are
needed to address these longitudinal changes in a large pediatric
cohort. Our findings reveal the importance of the Tim-3 marker in
pediatric HIV-1 infection and suggests that Tim-3 upregulation in
the older age group was driven by HIV-1 viral replication,
increased age, and longer duration of infection. The use of
reagents targeting Tim-3 or its ligand could potentially reverse
immunosenescence or exhaustion and other possible age-related
complications. We have shown that blocking Tim-3-Tim-3L
pathway either by addition of recombinant soluble Tim-3 (sTim-
3) glycoprotein as a competitor for Tim-3 ligand(s) or using a
blocking anti-Tim-3 mAB in vitro, increased expansion of antigen
specific CD8+T cells and T cell proliferation responses [30].
Furthermore, we are now beginning to unravel the Tim-3
signaling pathway mediating T cell inhibition [64,65], which
could unveil potential targets that reverse Tim-3 mediated events.
Applying these strategies to target Tim-3 in context of perinatal
HIV-1 infection together with improved cART delivery strategies
may therefore serve as a novel therapeutic to suppress viral
replication and mitigate age-related complications offering further
alternative treatment options in perinatal HIV-1 infection.
Supporting Information
Figure S1 A positive correlation between PD-1+CD4+ T
cells and HIV plasma viral load (VL) in children. Scatter
plots showing correlation between HIV-1 plasma viral load (VL)
and Tim-3+CD4+ T cells, and PD-1+CD4+ T cells in children (A
and C) and adolescents (B and D) respectively. PD-1+CD4+ T cells
show a significant direct correlation with HIV-1 plasma viral load
(VL) in children with shorter duration of HIV infection (Spearman
r= 0.88, *p= 0.033).
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